diff --git a/paper/paper.bib b/paper/paper.bib
index 8030cf0..71c2a8b 100644
--- a/paper/paper.bib
+++ b/paper/paper.bib
@@ -54,18 +54,6 @@ @article{Zerrouk2020
   publisher={Nature Publishing Group UK London}
 }
 
-@article{Srivastava2018,
-  title={A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target},
-  author={Srivastava, Prashant K and van Eyll, Jonathan and Godard, Patrice and Mazzuferi, Manuela and Delahaye-Duriez, Andree and Van Steenwinckel, Juliette and Gressens, Pierre and Danis, Benedicte and Vandenplas, Catherine and Foerch, Patrik and others},
-  journal={Nature communications},
-  volume={9},
-  number={1},
-  pages={3561},
-  year={2018},
-  doi={10.1038/s41467-018-06008-4},
-  publisher={Nature Publishing Group UK London}
-}
-
 @article{Collombet2017,
   title={Logical modeling of lymphoid and myeloid cell specification and transdifferentiation},
   author={Collombet, Samuel and van Oevelen, Chris and Sardina Ortega, Jose Luis and Abou-Jaoud{\'e}, Wassim and Di Stefano, Bruno and Thomas-Chollier, Morgane and Graf, Thomas and Thieffry, Denis},
diff --git a/paper/paper.md b/paper/paper.md
index a775527..ed17f38 100644
--- a/paper/paper.md
+++ b/paper/paper.md
@@ -45,13 +45,13 @@ for toxic unexpected side effects [@Bolouri2003; @Huang2019]. Finally, regulator
 
 # Statement of need
 
-As a general rule, the development of **NORDic** relies on avoiding *ad hoc* solutions, by implementation of approaches which are relevant to all kinds of 
-diseases regardless of the level of knowledge present in the literature --contrary to approaches which rely on knowing the relation between membrane receptors 
-and a set of genes which activity characterizes the presence of the disease, for instance "Causal Reasoning Analytical Framework for Target discovery" 
-(CRAFT) [@Srivastava2018]. Please refer to Figure 1 for an overview of the package. Solutions proposed in this package emphasize on, first, the modularity of the methods, by providing functions which can tackle different 
+The development of **NORDic** relies on avoiding *ad hoc* solutions, by implementation of approaches which are relevant to all kinds of 
+diseases regardless of the level of knowledge present in the literature. Please refer to Figure 1 for an overview of the package. Solutions proposed in this package emphasize on, first, the modularity of the methods, by providing functions which can tackle different 
 types of regulatory dynamics for instance; second, on the transparency of the approaches, by allowing the finetuning of each method through parameters with a clearly 
 defined impact on the result.
 
+![Overview of the different modules in NORDic.](overview.png)
+
 ## Automated identification of disease-related Boolean networks
 
 Most prior works about building Boolean networks assume the existence of a preselected set of known regulatory 
@@ -79,8 +79,6 @@ Module **NORDic PMR** detects master regulators in a Boolean network, given exam
 (groups of) master regulators takes into account the network topology as well as its dynamics with respect to the diseased profiles. The approach, based on a machine learning 
 algorithm solving the influence maximization problem [@Kempe2003], is described in @Reda22022.
 
-![Overview of the different modules in NORDic.](overview.png)
-
 ## Novel approaches for scoring drug effects & repurposing drugs
 
 **NORDic** also proposes to tackle two problems related to drug repurposing: first, drug scoring, based on its ability to reverse the diseased gene activity profile